HepaStem seems most promising pipeline agent for decompensated cirrhosis due to NASH: GlobalData
Express Pharma
SEPTEMBER 12, 2023
tumor formation, immune reactions, and therapy failure). tumor formation, immune reactions, and therapy failure). HepaStem is projected to hit the US market in Q1 2027, while BioVie’s BIV201 is anticipated to be marketed in Q4 2028.
111 
Let's personalize your content